Statements (45)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:Company
|
gptkbp:acquisition |
gptkb:OSI_Pharmaceuticals
gptkb:Iveric_Bio |
gptkbp:awards |
gptkb:Top_Employer_Japan
Diversity_&_Inclusion_Award Best_Workplaces_in_Japan |
gptkbp:CEO |
gptkb:Kenji_Yasukawa
|
gptkbp:clinicalTrials |
invests heavily in clinical research
conducts numerous clinical trials worldwide |
gptkbp:collaborations |
with academic institutions
with healthcare organizations with research institutes |
gptkbp:employeeCount |
around 17,000
|
gptkbp:focus_area |
neurology
rare diseases dermatology cardiovascular diseases infectious diseases pain management transplantation |
gptkbp:founded |
2005
|
gptkbp:global_presence |
operates in over 70 countries
|
gptkbp:headquarters |
gptkb:Tokyo,_Japan
|
https://www.w3.org/2000/01/rdf-schema#label |
Astellas Pharma
|
gptkbp:industry |
pharmaceuticals
|
gptkbp:market |
strong_presence_in_Europe
strong_presence_in_Asia strong_presence_in_North_America |
gptkbp:partnerships |
various biotech companies
|
gptkbp:patentCitation |
holds numerous patents in pharmaceuticals
|
gptkbp:philanthropy |
supports various health initiatives
contributes to community health programs engages in educational initiatives |
gptkbp:products |
oncology drugs
immunosuppressants urology drugs |
gptkbp:researchAndDevelopment |
focus on innovative medicines
|
gptkbp:revenue |
$12.5 billion (2022)
|
gptkbp:stockExchange |
4503 (TSE)
|
gptkbp:subsidiary |
gptkb:Astellas_US_LLC
gptkb:Astellas_Pharma_Europe_Ltd. gptkb:Astellas_Pharma_Canada_Inc. |
gptkbp:sustainability_initiatives |
social responsibility
environmental responsibility governance practices |